The Future of Eye Care: My Next Chapter with Outcome Capital

The Future of Eye Care: My Next Chapter with Outcome Capital
By Paul Ryb

After three decades in global investment banking and a deeply personal journey with vision loss, I’m thrilled to take on this new challenge as Managing Director at Outcome Capital, where I’ll be leading our dedicated ophthalmology practice.

This role brings together every chapter of my career and life: from my early days at HSBC James Capel to Lehman Brothers and Royal Bank of Scotland, to my later work with the National Health Service (NHS), Royal National Institute of the Blind (RNIB) and King’s Access Technology Group. 

It also brings something more personal. Since losing my sight to macular degeneration in 2007, I’ve focused on mentoring, advocacy, and investing in solutions that improve the lives of people living with vision loss. As Vice Chair of The Macular Society UK and serving on the Investment Committee of Fight for Sight, one of my missions is to guide funding toward impactful ophthalmic research and innovation.

That mission now scales with Outcome. With over 2.2 billion people worldwide impacted by visual impairment, the need for transformation in diagnostics, devices, therapeutics, and AI couldn’t be more urgent. From the Bausch + Lomb acquisition of ELIOS Vision to the seed-stage ventures I’ve helped guide, I’ve witnessed first-hand that meaningful change happens when capital, insight, and patient perspective align. At Outcome, I have the opportunity to combine all three.

Outcome’s track record in helping clients de-risk their portfolios and the firm’s strategy-led approach make it a powerful platform for advancing ophthalmic breakthroughs. As I take on this role, I look forward to helping companies navigate the path from early-stage development into strategic collaboration and successful exits and IPOs to bring bold ideas to patients.

For me, this is both a professional milestone and a full-circle moment. I’m joining a team that knows how to turn courageous science into real-world solutions. We believe in supporting the best ophthalmology programmes, driving real patient outcomes within the fastest growing challenge in the life sciences today.

Let’s get to work so that the next wave of ophthalmic breakthroughs doesn’t just get funded but reaches the patients who need them most.